Table of Contents
ABOUT THIS PROFILE
- PharmaVitae Explorer database
- Chapter structure
- Quarterly news update
- Company introduction
- Company sales
- Company financials
- Key products and competitors
EXECUTIVE SUMMARY
- Key findings
- Prescription pharmaceutical sales and growth rate performance, 2002 - 14
- Financial performance, 2002 - 14
- Chugai: PharmaVitae forecasts at a glance
- Strategic insight
- (Untitled sub-section)
- Chugai dominates the Japanese mAb landscape
- SWOT analysis
- Strengths
- Weaknesses
- Opportunities
- Threats
QUARTERLY NEWS UPDATE
- Product developments
- Deals and alliances
- M&A activity
- Company announcements
- Future product milestones
COMPANY INTRODUCTION
- Key findings
- Background
- Key corporate developments
- M&A history
- Consolidation into the Roche group in October 2002
- Divestments since the Roche merger have promoted Rx focus
- Current corporate structure
COMPANY SALES
- Key findings
- Prescription pharmaceutical sales and growth rate analysis, 2002 - 14
- Product analysis
- Product analysis, 2002 - 08
- Product analysis, 2008 - 14
- Therapy area analysis
- Geographic analysis
- Launch/core/expiry analysis
- Explanation of launch/core/expiry analysis
- Launch analysis, 2008 - 14
- Core analysis, 2008 - 14
- Expiry analysis, 2008 - 14
- Launch/core/expiry configuration, 2008 - 14
- Molecule type analysis
- Externalization analysis
COMPANY FINANCIALS
- Key findings
- Reconciliation between PharmaVitae-formatted prescription pharma sales and
company-reported total sales, 2002 - 08
- Operating costs and profit analysis
- Operating costs and profit analysis, 2002 - 08
- Operating cost ratio and profit margin analysis, 2002 - 08
- Operating cost ratio and profit margin analysis, 2008 - 14
- Operating costs and profit analysis, 2008 - 14
KEY PRODUCTS AND COMPETITORS
- Key findings
- Overview
- Oncology
- (Untitled sub-section)
- Herceptin
- Rituxan
- Neutrogin
- Tarceva
- Immunology & inflammation
APPENDIX
- R&D pipeline
- References
- Abbreviations
- Exchange rates
TABLES
- Table: Chugai - PharmaVitae forecasts at a glance
- Table: Chugai key product developments, 2009
- Table: Chugai product deals and alliances, 2009
- Table: Chugai technology deals and alliances, 2009
- Table: Chugai M&A activity, 2009
- Table: Chugai company announcements, 2009
- Table: Chugai future product milestones, 2009 - 11
- Table: Chugai product portfolio overview ($m), 2002 - 08
- Table: Chugai product portfolio overview ($m), 2008 - 14
- Table: Chugai prescription pharmaceutical sales by therapy area ($m), 2008
- 14
- Table: Chugai prescription pharmaceutical sales by geographic region ($m),
2008 - 14
- Table: Chugai launch portfolio overview ($m), 2008 - 14
- Table: Chugai core portfolio overview ($m), 2008 - 14
- Table: Chugai expiry portfolio overview ($m), 2008 - 14
- Table: Chugai prescription pharmaceutical sales by molecule type ($m),
2008 - 14
- Table: Chugai prescription pharmaceutical sales by source ($m), 2008 - 14
- Table: Total Chugai sales by business unit ($m), 2002 - 08
- Table: Chugai operating revenue/cost analysis ($m), 2002 - 08
- Table: Chugai operating cost ratio analysis (% of total revenues), 2002 -
08
- Table: Chugai operating cost ratio analysis (% of total revenues), 2008 -
14
- Table: Chugai operating revenue/cost analysis ($m), 2008 - 14
- Table: Key products overview
- Table: Avastin: overview
- Table: Avastin: sales forecast ($m), 2008 - 14
- Table: Herceptin: overview
- Table: Herceptin: sales forecast ($m), 2008 - 14
- Table: Rituxan: overview
- Table: Rituxan: sales forecast ($m), 2008 - 14
- Table: Neutrogin: overview
- Table: Neutrogin: sales forecast ($m), 2008 - 14
- Table: Tarceva: overview
- Table: Tarceva: sales forecast ($m), 2008 - 14
- Table: Epogin: overview
- Table: Epogin: sales forecast ($m), 2008 - 14
- Table: R-744/Mircera: overview
- Table: R-744/Mircera: sales forecast ($m), 2008 - 14
- Table: Actemra: overview
- Table: Actemra: sales forecast ($m), 2008 - 14
- Table: Tamiflu: overview
- Table: Tamiflu: sales forecast ($m), 2008 - 14
- Table: Stockpiling and prescription Tamiflu sales ($m), 2003 - 08
- Table: Pegasys: overview
- Table: Pegasys: sales forecast ($m), 2008 - 14
- Table: Evista: overview
- Table: Evista: sales forecast ($m), 2008 - 14
- Table: R-484/Boniva: overview
- Table: R-484/Bomiva: sales forecast ($m), 2008 - 14
- Table: Chugai' s R&D pipeline (Phase I - registration)
- Table: Exchange rates, 2009
FIGURES
- Figure: The PharmaVitae Explorer
- Figure: Chugai prescription pharmaceutical performance, sales ($m) and
growth rate (%), 2002 - 14
- Figure: Chugai' s financial performance ($m), 2002 - 14
- Figure: Roche/Genentech/Chugai alliance
- Figure: Chugai dependency on mAb portfolio as a % of total revenues, 2002
- 14
- Figure: Total Japanese mAb market sales by company, 2002 - 14 ($m)
- Figure: Chugai pharmaceutical sales growth by source company, 2002 - 14
($m)
- Figure: Chugai SWOT analysis
- Figure: Current corporate structure
- Figure: Chugai prescription pharmaceutical performance, sales ($m) and
growth rate (%), 2002 - 14
- Figure: Key product sales ($m), 2002 - 14
- Figure: Chugai key sales growth drivers and resistors ($m), 2002 - 08
- Figure: Chugai key sales growth drivers and resistors ($m), 2008 - 14
- Figure: Chugai prescription pharmaceutical sales by therapy area ($m),
2002 - 14
- Figure: Chugai prescription pharmaceutical sales by geographic region
($m), 2002 - 14
- Figure: Chugai launch/core/expiry configuration ($m), 2008 - 14
- Figure: Chugai prescription pharmaceutical sales by molecule type ($m),
2002 - 14
- Figure: Chugai prescription pharmaceutical sales by source ($m), 2002 - 14
- Figure: Chugai operating revenue/cost analysis ($m), 2002 - 14
|
Related Report
|
View Cart
